FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Business Wire
Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCSEstablished U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansionActive discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programsWebcasts will be held on February 26, 2026, to discuss the Company’s recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed President of Median eyonis Inc.Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI (TEM) had its price target lowered by Morgan Stanley from $85.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
- Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision MedicineBusiness Wire
- Tempus AI (TEM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TEM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sellMarketBeat
- Tempus to Participate in the Morgan Stanley Technology, Media & Telecom ConferenceBusiness Wire
- Tempus AI: No AI Interruption Detected [Seeking Alpha]Seeking Alpha
TEM
Earnings
- 2/24/26 - Beat
TEM
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/2/26 - Form 144
- TEM's page on the SEC website